TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05967871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
Study: NCT05308823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent
Description: The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
Study: NCT05763849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure Treatment (IE)
Description: Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Based Treatment (FBT)
Description: Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
Study: NCT04398719

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: [11C]PBR28
Description: The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose lipopolysaccharide
Description: Subjects will receive intravenous lipopolysaccharide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose lipopolysaccharide
Description: Subjects will receive intravenous lipopolysaccharide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal Capsaicin
Description: A small dose of capsaicin will be administered by intradermal injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intradermal Capsaicin
Description: A small dose of capsaicin will be administered by intradermal injection.
Study: NCT05064722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Forming Magnets (SFM)
Description: To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Forming Magnets (SFM)
Description: To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
Study: NCT05894694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first-line scheme+compound kushen injection
Description: FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.

Intervention type: DRUG
Group type: OTHER
Intervention: palliative care group first-line scheme
Description: FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
Study: NCT04943848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHSC-DIPGVax
Description: Off-the-shelf, neoantigen heat shock protein vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHSC-DIPGVax
Description: Off-the-shelf, neoantigen heat shock protein vaccine
Study: NCT05201859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
Study: NCT04943848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHSC-DIPGVax
Description: Off-the-shelf, neoantigen heat shock protein vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHSC-DIPGVax
Description: Off-the-shelf, neoantigen heat shock protein vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
Study: NCT05116709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6005 injection
Description: Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
Study: NCT06462456

Intervention type: DEVICE
Intervention: Verofilcon A spherical soft contact lenses
Description: Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)

Intervention type: DEVICE
Intervention: Verofilcon A toric soft contact lenses
Description: Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
Study: NCT06402162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The study will include 40 tennis players diagnosed with rotator cuff lesions who meet the inclusion criteria. The 1st group will be randomly divided into 2 groups as control (n=20) and 2nd group as core exercise (n=20). Unlike the control group, core exercises will be added to the routine exercise program of tennis players once a day, 3 days a week for 8 weeks.
Study: NCT06581237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eat2Win App
Description: Voluntary use of the app will occur throughout the sport season.
Study: NCT05723601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol vaginal cream
Description: Participants will use vaginal estradiol cream for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol vaginal cream
Description: Participants will use vaginal estradiol cream for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Vaginal Tablet
Description: Participants will use vaginal estradiol tablet for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Vaginal Tablet
Description: Participants will use vaginal estradiol tablet for 3 months
Study: NCT04952571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Bevacizumab
Description: Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Bevacizumab
Description: Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion.
Study: NCT06638788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee extension
Description: Participants will perform 20, 40, and 60% of thier 1 rep maximum (1RM) at 18, 12, and 6 reps respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee extension
Description: Participants will perform 20, 40, and 60% of thier 1 rep maximum (1RM) at 18, 12, and 6 reps respectively.
Study: NCT06642792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK129
Description: Subjects receive AK129 intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK129
Description: Subjects receive AK129 intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: Subjects receive AK117 intravenously.
Study: NCT06639529

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of the expression of CXCL3 in various tissues
Description: 1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of the expression of CXCL3 in various tissues
Description: 1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of the expression of CXCL3 in various tissues
Description: 1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.
Study: NCT06637098

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral tube feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gastrostomy feeding
Description: Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
Study: NCT06644820

Intervention type: DIAGNOSTIC_TEST
Intervention: radiology
Description: Chest x ray posteroanterior view and lateral view.~CT. chest without contrast:~To assess the underlying lung pathology e.g. multiple bullae, interstitial lung disease (ILD) , cavitating lesions or nodules.

Intervention type: DIAGNOSTIC_TEST
Intervention: radiology
Description: Chest x ray posteroanterior view and lateral view.~CT. chest without contrast:~To assess the underlying lung pathology e.g. multiple bullae, interstitial lung disease (ILD) , cavitating lesions or nodules.
Study: NCT06460155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 methods intervention
Description: Stu All participants will undergo all three methods being studied: epidurogram (gold standard), CompuFlo CathCheck, and physical exam in PACU following epidural placement.
Study: NCT06645236

Intervention type: DEVICE
Group type: OTHER
Intervention: therascreen® KRAS RGQ PCR Kit
Description: The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)
Study: NCT06643156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 10mg/20mg/40mg
Description: 0.5/1/2×20mg power for oral suspension taken orally
Study: NCT05921786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiological system
Description: Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiphoton microscope
Description: Multiphoton microscope acquires high-resolution image based on nonlinear optics and can be used for detect biological specimens.
Study: NCT05201859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: An oral anticancer agent that can be converted into 5-Fu in vivo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: An oral anticancer agent that can be converted into 5-Fu in vivo.
Study: NCT05071326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led health coaching
Description: This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
Study: NCT05038839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Given PO
Study: NCT04971733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: E2814 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2814
Description: E2814 intravenous infusion.
Study: NCT05525520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP547
Description: Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT05423613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
Study: NCT06477601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigning cooling agent type cigarettes
Description: This study is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol cigarettes but allows cooling agent cigarettes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigning traditional tobacco type cigarettes
Description: This comparison group is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol and cooling agent cigarettes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assigning menthol type cigarettes
Description: This comparison group is for where the Food and Drug Administration does not ban menthol cigarettes.
Study: NCT05870072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: In addition to balance exercises, random name-word generation, counting the days of the week forward and backward, counting the months of the year forward and backward, subtracting 3 by 3 numbers from 300 to 900 starting from a random number, adding 7 from 1 to 100 and adding 100 Cognitive tasks such as counting tasks by subtracting 7 will be given. While testing dual-task performance, subjects will be asked to perform both tasks without prioritizing and do their best, and will be warned not to stop thinking. In dual-task training, the additional task to be assigned to the motor task will initially be of low complexity and novelty, and will progress to a high degree of complexity and novelty in the training process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesthetic motor imagery training
Description: Kinesthetic motor imagery training will be planned according to the PETTLEP model. In our study, a single standard motor imagery frame will be created for the subjects. Before starting the motor imagery sessions, individuals will be given an introductory motor imagery session. How to visualize from first-person and third-person perspectives will be explained practically. Motor imagery training will be done in a quiet environment with the door and window closed in order to minimize the external factors that will distract the individual and prevent him from focusing, and the individual will be asked to sit in the motor imagery training sessions. a comfortable chair in the position they feel most comfortable in. Individuals will have their eyes closed throughout the entire motor imagery training. At the beginning of the session, approximately 5 minutes of relaxation exercise will be performed to maximize attention during motor imagery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercises
Description: Balance exercises will begin with approximately 5 minutes of warm-up exercises and will end with approximately 5 minutes of cool-down exercises at the end of each session. Balance exercises; Static standing on flat ground for 30 seconds with feet together, standing in tandem position for 30 seconds, standing on one leg for 30 seconds, and toes for 30 seconds, one foot airborne backwards, one foot airborne knee flexion slightly squat, one foot airborne knee extension slightly squat, going on the toes, turning with the heel, and multi-directional stretching exercises with eyes open and closed on one leg on the balance board. Each exercise will be performed with 10 repetitions for both lower extremities. Exercises will be applied once a day, 3 days a week for 6 weeks. The exercise program will be accompanied by a physiotherapist and groups of 6-10 people with similar suitability will be formed for the session hours.
Study: NCT06500156

Intervention type: OTHER
Intervention: Fluid challenge
Description: Rapid infusion (\< 15 minutes) of a fluid bolus of crystalloids (200 to 500cc)
Study: NCT06570746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedative
Description: Sedation is applied before the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedative
Description: Sedation is applied before the procedure
Study: NCT06570850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin Sodium Methanesulfonate
Description: Intravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin Sodium Methanesulfonate plus Fosfomycin
Description: Intravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.